CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

But a recent coverage change by a major pharmacy benefit manager may force many to decide how much they're willing to pay for the drug or whether they want to try another weight loss option. As of ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS Caremark alerted customers who used Zepbound in May, writing them in a letter, “This change is happening because there’s another covered medication that’s safe and effective for your ...

Eli Lilly's Zepbound faces insurance hurdles as coverage changes could spike out-of-pocket costs for millions relying on weight loss medications. Zepbound users face new hurdles as CVS drops the drug ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical ...

As of July 1, CVS dropped Zepbound from preferred coverage for those covered by its pharmacy benefit manager, Caremark. Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the ...